Skip navigation

Rare.ases are chronic and require close, long term monitoring. Medline . Whether through infection or other causes, this balance can be upset and auto reactive T cells allowed to proliferate and migrate to the eye. chat cpl, Kosmeder J 2nd, Pezzuto FM. The retina is the light-sensitive part of the eye that focuses the images you see and sends them to the brain. It is a leading cause of blindness in the United States and in the world. Your ophthalmologist may refer you to another specialist if they suspect an underlying condition is causing your uveitis. Current options and emerging therapies for anterior ocular inflammatory disease. If you have an infection, your doctor will prescribe antibiotics. Rodriguez A, Calonge M, Pedroza-Seres M, Akova A, messier EM, D’Amoco DJ, et al. Swift Secrets Of Laser Eye Surgery Guidance | Suggestions To The ViewHence, uveitis is inflammation of any of these components and may also include other surrounding tissues such as sclera, retina, and optic nerve. 1 Uveitis is often idiopathic but may be triggered by genetic, traumatic, immune, or infectious mechanisms.

The replay may be accessed by dialing (855) 859-2056 within theU.S.andCanadaor (404) 537-3406 from international locations, Conference ID Number: 9987331. A replay of the webcast will also be available on the corporate website during that time. About pSivida Corp.pSivida Corp.( ), headquartered inWatertown, MA, is a leader in the development of sustained release, drug delivery products for treating eye diseases. pSivida has developed three of only fourFDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in theU.S.and three EU countries. Retisert, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb.pSivida’s lead product candidate, Medidur, a micro-insert for posterior uveitis being independently developed, is currently in pivotal Phase 3 clinical trials, with an NDA anticipated in 2017. pSivida’s pre-clinical development program is focused on using its core platform technologies Durasert and Tethadur to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis and other diseases.To learn more about pSivida please visit and connect on Twitter , LinkedIn , Facebook and Google+ . SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements include uncertainties with respect to: our ability to obtain needed capital; our ability to achieve profitable operations; potential declines in Retisert royalties; fluctuations in our operating results; further impairment of our intangible assets; our ability to obtain marketing approvals for and successfully commercialize Medidur for posterior segment uveitis; performance by CROs, vendors and investigators; timing of filing marketing approval applications for Medidur; acceptability of data to be filed in support of Medidur marketing applications; maintenance of orphan designation for Medidur, potential off-label sales of ILUVIEN for posterior segment uveitis; successful commercialization of, and receipt of revenues from, ILUVIEN for DME; Alimeras ability to continue as a going concern; the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; consequences of fluocinolone acetonide side effects; outcome of dispute with Alimera on commercialization expenses; any exercise by Pfizer of its option with respect to the latanoprost product; our ability to develop Tethadur to successfully deliver large biologic molecules and develop products using it; efficacy and future development of severe OA implant by us; our ability to successfully develop product candidates, initiate and complete clinical trials and receive regulatory approvals; our ability to market and sell products; the success of current and future license agreements; termination or breach of current license agreements; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; effects of potential U.K.

For the original version including any supplementary images or video, visit

And some herbs and supplements are good for eye health. Infections or tumours occurring within the eye or in other parts of the body. No deaths due to iritis or uveitis have been reported. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Symptoms of uveitis can vary depending on the location of the inflammation. She became board certified by the American Board of Ophthalmology in 1998 and recertified in 2008. An Examination Of Rudimentary Keratoconus Systems | Advice To The ViewManagement of the red eye for the primary care physician. In a later study, researchers found that surgical implantation of the Retisert device was equally effective as systemic corticosteroid medications for the treatment of non-infectious intermediate, posterior and diffuse uveitis over a period of 24 months. Radiology X-ray may be used to show coexisting arthritis and chest X-ray may be helpful in sarcoidosis. She currently practices at One to One Eye Care in San Diego, A.

Leave a Reply

Your email address will not be published. Required fields are marked *